drugset / Trial / NCT05060276
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.
Timeline
- Start
- 2022-12
- Primary completion
- 2024-05
- Completion
- 2024-12
Outcome
Outcome not reported
Stopped: “Protocol changed to Phase 2”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STI-3258 | Unknown | 8 mg/kg | Intravenous |
| Subject | STI-3258 | Unknown | 12 mg/kg | Intravenous |
| Subject | STI-3258 | Unknown | 16 mg/kg | Intravenous |
| Subject | STI-3258 | Unknown | 20 mg/kg | Intravenous |
| Subject | STI-3258 | Unknown | 24 mg/kg | Intravenous |